| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 136 | 2023 | 253 | 14.900 |
Why?
|
| Staphylococcal Infections | 45 | 2023 | 144 | 8.290 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 35 | 2023 | 107 | 7.430 |
Why?
|
| Infection Control | 70 | 2021 | 149 | 7.360 |
Why?
|
| Anti-Bacterial Agents | 74 | 2023 | 333 | 6.610 |
Why?
|
| Intensive Care Units | 57 | 2023 | 266 | 4.430 |
Why?
|
| Bacteremia | 33 | 2019 | 94 | 4.220 |
Why?
|
| Humans | 307 | 2025 | 25692 | 2.950 |
Why?
|
| Enterococcus | 25 | 2014 | 51 | 2.550 |
Why?
|
| Community-Acquired Infections | 19 | 2022 | 61 | 2.530 |
Why?
|
| Klebsiella pneumoniae | 19 | 2022 | 57 | 2.450 |
Why?
|
| Chlorhexidine | 19 | 2023 | 52 | 2.380 |
Why?
|
| Drug Resistance, Microbial | 40 | 2015 | 62 | 2.370 |
Why?
|
| Drug Resistance, Bacterial | 16 | 2021 | 47 | 2.250 |
Why?
|
| Gram-Positive Bacterial Infections | 22 | 2014 | 52 | 2.220 |
Why?
|
| Klebsiella Infections | 16 | 2022 | 51 | 2.200 |
Why?
|
| Disease Outbreaks | 30 | 2023 | 75 | 1.990 |
Why?
|
| Carbapenems | 11 | 2021 | 39 | 1.960 |
Why?
|
| Anti-Infective Agents | 13 | 2023 | 33 | 1.950 |
Why?
|
| Enterobacteriaceae Infections | 18 | 2021 | 38 | 1.930 |
Why?
|
| Catheterization, Central Venous | 14 | 2010 | 32 | 1.930 |
Why?
|
| Hospitals | 34 | 2023 | 143 | 1.890 |
Why?
|
| Carrier State | 20 | 2019 | 47 | 1.880 |
Why?
|
| Surgical Wound Infection | 11 | 2019 | 70 | 1.820 |
Why?
|
| beta-Lactamases | 18 | 2023 | 81 | 1.810 |
Why?
|
| Population Surveillance | 15 | 2018 | 103 | 1.790 |
Why?
|
| Bacterial Proteins | 16 | 2021 | 74 | 1.760 |
Why?
|
| AIDS-Related Opportunistic Infections | 19 | 2010 | 35 | 1.700 |
Why?
|
| Chicago | 42 | 2021 | 869 | 1.650 |
Why?
|
| Anti-Infective Agents, Local | 15 | 2023 | 41 | 1.640 |
Why?
|
| Male | 124 | 2025 | 13917 | 1.640 |
Why?
|
| Baths | 10 | 2023 | 21 | 1.590 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 16 | 2020 | 48 | 1.550 |
Why?
|
| Female | 119 | 2025 | 14273 | 1.520 |
Why?
|
| Practice Guidelines as Topic | 13 | 2018 | 284 | 1.490 |
Why?
|
| Staphylococcus aureus | 17 | 2023 | 63 | 1.480 |
Why?
|
| Vancomycin Resistance | 14 | 2014 | 26 | 1.470 |
Why?
|
| HIV Infections | 13 | 2013 | 457 | 1.440 |
Why?
|
| Pneumonia, Pneumocystis | 19 | 2010 | 27 | 1.420 |
Why?
|
| Adult | 86 | 2025 | 7336 | 1.370 |
Why?
|
| Vancomycin | 14 | 2012 | 50 | 1.350 |
Why?
|
| Hand Disinfection | 13 | 2019 | 22 | 1.330 |
Why?
|
| Enterobacteriaceae | 14 | 2020 | 34 | 1.310 |
Why?
|
| Middle Aged | 90 | 2025 | 8403 | 1.270 |
Why?
|
| Methicillin Resistance | 9 | 2012 | 23 | 1.250 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 6 | 2021 | 12 | 1.210 |
Why?
|
| Hospitalization | 18 | 2025 | 292 | 1.150 |
Why?
|
| Probiotics | 2 | 2018 | 19 | 1.110 |
Why?
|
| Equipment Contamination | 12 | 2019 | 23 | 1.110 |
Why?
|
| Risk Factors | 36 | 2021 | 2224 | 1.100 |
Why?
|
| Gloves, Protective | 7 | 2019 | 15 | 1.100 |
Why?
|
| Medical Staff, Hospital | 3 | 2017 | 16 | 1.090 |
Why?
|
| Communicable Diseases | 5 | 2023 | 21 | 1.080 |
Why?
|
| Bacterial Infections | 11 | 2021 | 41 | 1.070 |
Why?
|
| Prevalence | 20 | 2023 | 435 | 1.050 |
Why?
|
| Internal Medicine | 3 | 2017 | 24 | 1.040 |
Why?
|
| Clostridium Infections | 4 | 2018 | 20 | 1.010 |
Why?
|
| Gram-Negative Bacterial Infections | 9 | 2015 | 24 | 0.970 |
Why?
|
| Guideline Adherence | 8 | 2014 | 59 | 0.960 |
Why?
|
| Skin | 11 | 2018 | 99 | 0.950 |
Why?
|
| Genomics | 7 | 2022 | 53 | 0.920 |
Why?
|
| Sepsis | 9 | 2023 | 119 | 0.890 |
Why?
|
| United States | 39 | 2023 | 1943 | 0.880 |
Why?
|
| Aged | 59 | 2024 | 8501 | 0.860 |
Why?
|
| Antibiotic Prophylaxis | 5 | 2016 | 26 | 0.840 |
Why?
|
| Drug Utilization Review | 3 | 2009 | 4 | 0.780 |
Why?
|
| Microbial Sensitivity Tests | 26 | 2023 | 75 | 0.770 |
Why?
|
| Mass Screening | 4 | 2015 | 168 | 0.770 |
Why?
|
| Prisons | 3 | 2013 | 8 | 0.760 |
Why?
|
| Molecular Typing | 4 | 2021 | 9 | 0.760 |
Why?
|
| Q Fever | 2 | 2016 | 5 | 0.740 |
Why?
|
| Catheter-Related Infections | 5 | 2023 | 15 | 0.740 |
Why?
|
| Illinois | 12 | 2021 | 223 | 0.740 |
Why?
|
| Catheters, Indwelling | 6 | 2006 | 21 | 0.740 |
Why?
|
| Physicians | 6 | 2016 | 112 | 0.730 |
Why?
|
| Personnel, Hospital | 7 | 2009 | 16 | 0.710 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2009 | 7 | 0.700 |
Why?
|
| Protective Clothing | 3 | 2019 | 8 | 0.700 |
Why?
|
| Adolescent | 27 | 2022 | 2076 | 0.690 |
Why?
|
| Cost-Benefit Analysis | 4 | 2015 | 124 | 0.680 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 23 | 0.680 |
Why?
|
| Prospective Studies | 29 | 2024 | 1633 | 0.680 |
Why?
|
| Long-Term Care | 11 | 2019 | 54 | 0.670 |
Why?
|
| Ventilation | 2 | 2017 | 4 | 0.670 |
Why?
|
| Catheterization | 6 | 2007 | 39 | 0.660 |
Why?
|
| Genotype | 4 | 2019 | 326 | 0.660 |
Why?
|
| Public Health | 3 | 2019 | 66 | 0.660 |
Why?
|
| Quality of Health Care | 7 | 2005 | 117 | 0.660 |
Why?
|
| Evolution, Molecular | 2 | 2017 | 6 | 0.650 |
Why?
|
| Pseudomonas Infections | 11 | 2017 | 40 | 0.640 |
Why?
|
| Smoke | 1 | 2018 | 4 | 0.630 |
Why?
|
| Conflict of Interest | 1 | 2018 | 10 | 0.620 |
Why?
|
| Alveolar Bone Loss | 3 | 2013 | 4 | 0.620 |
Why?
|
| Mupirocin | 6 | 2023 | 17 | 0.610 |
Why?
|
| Registries | 4 | 2025 | 170 | 0.610 |
Why?
|
| Antimicrobial Stewardship | 2 | 2018 | 8 | 0.610 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2006 | 41 | 0.600 |
Why?
|
| Patient Isolation | 7 | 2010 | 18 | 0.590 |
Why?
|
| Primary Prevention | 1 | 2018 | 32 | 0.590 |
Why?
|
| DNA, Bacterial | 7 | 2017 | 39 | 0.590 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 3 | 2008 | 6 | 0.580 |
Why?
|
| Genome, Bacterial | 5 | 2017 | 13 | 0.570 |
Why?
|
| Case-Control Studies | 11 | 2023 | 532 | 0.570 |
Why?
|
| Medical Audit | 1 | 2017 | 6 | 0.570 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 5 | 0.570 |
Why?
|
| Hospitals, Public | 11 | 2015 | 25 | 0.560 |
Why?
|
| Patient Care | 3 | 2013 | 29 | 0.560 |
Why?
|
| Bacterial Typing Techniques | 3 | 2016 | 10 | 0.560 |
Why?
|
| Acinetobacter Infections | 3 | 2019 | 6 | 0.550 |
Why?
|
| Retrospective Studies | 25 | 2022 | 3220 | 0.550 |
Why?
|
| Nasal Cavity | 4 | 2014 | 30 | 0.550 |
Why?
|
| Critical Care | 8 | 2018 | 180 | 0.540 |
Why?
|
| Cesarean Section | 1 | 2016 | 24 | 0.540 |
Why?
|
| Hospitals, Teaching | 9 | 2018 | 29 | 0.540 |
Why?
|
| Acinetobacter baumannii | 2 | 2019 | 5 | 0.520 |
Why?
|
| Lactobacillus | 1 | 2016 | 18 | 0.520 |
Why?
|
| Doxycycline | 1 | 2016 | 16 | 0.520 |
Why?
|
| State Medicine | 1 | 2015 | 3 | 0.510 |
Why?
|
| Pneumonia, Ventilator-Associated | 5 | 2023 | 19 | 0.510 |
Why?
|
| Aerosols | 3 | 2013 | 22 | 0.510 |
Why?
|
| Health Information Exchange | 1 | 2015 | 3 | 0.510 |
Why?
|
| Hand | 4 | 2008 | 32 | 0.510 |
Why?
|
| Health Personnel | 4 | 2021 | 102 | 0.500 |
Why?
|
| Health Resources | 2 | 2010 | 23 | 0.490 |
Why?
|
| Drug Utilization | 7 | 2007 | 20 | 0.490 |
Why?
|
| Delivery of Health Care | 6 | 2023 | 143 | 0.490 |
Why?
|
| Anesthesia | 1 | 2015 | 27 | 0.480 |
Why?
|
| Anesthesiology | 1 | 2015 | 26 | 0.470 |
Why?
|
| Time Factors | 19 | 2022 | 1336 | 0.470 |
Why?
|
| Pharynx | 1 | 2014 | 12 | 0.460 |
Why?
|
| Specimen Handling | 5 | 2017 | 43 | 0.460 |
Why?
|
| Urinary Tract Infections | 6 | 2023 | 30 | 0.450 |
Why?
|
| Length of Stay | 5 | 2014 | 300 | 0.450 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 55 | 0.450 |
Why?
|
| Bacteria | 7 | 2017 | 72 | 0.450 |
Why?
|
| Platelet-Rich Plasma | 2 | 2016 | 80 | 0.450 |
Why?
|
| Child | 15 | 2023 | 1277 | 0.450 |
Why?
|
| Pneumococcal Vaccines | 2 | 2004 | 4 | 0.440 |
Why?
|
| Urban Population | 2 | 2021 | 149 | 0.430 |
Why?
|
| Program Evaluation | 3 | 2009 | 124 | 0.430 |
Why?
|
| Fungi | 1 | 2013 | 3 | 0.420 |
Why?
|
| Air Microbiology | 1 | 2013 | 5 | 0.420 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 11 | 2015 | 30 | 0.420 |
Why?
|
| Disease Transmission, Infectious | 5 | 2019 | 11 | 0.410 |
Why?
|
| Disease Notification | 2 | 2018 | 3 | 0.400 |
Why?
|
| Nursing Homes | 6 | 2020 | 36 | 0.400 |
Why?
|
| Molecular Epidemiology | 9 | 2021 | 27 | 0.400 |
Why?
|
| Students, Medical | 1 | 2012 | 47 | 0.400 |
Why?
|
| Staphylococcal Skin Infections | 3 | 2011 | 8 | 0.400 |
Why?
|
| Phenotype | 7 | 2021 | 292 | 0.390 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 27 | 0.390 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2009 | 7 | 0.390 |
Why?
|
| Catheterization, Peripheral | 3 | 2002 | 16 | 0.380 |
Why?
|
| Pharmacy Service, Hospital | 4 | 2006 | 11 | 0.380 |
Why?
|
| Streptococcal Infections | 2 | 2002 | 8 | 0.380 |
Why?
|
| Gram-Negative Bacteria | 11 | 2013 | 26 | 0.370 |
Why?
|
| Guidelines as Topic | 5 | 2009 | 61 | 0.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2010 | 60 | 0.370 |
Why?
|
| Hospital Costs | 2 | 2014 | 59 | 0.370 |
Why?
|
| Escherichia coli | 7 | 2023 | 54 | 0.370 |
Why?
|
| Water Microbiology | 3 | 2020 | 10 | 0.370 |
Why?
|
| Hospital Mortality | 8 | 2010 | 131 | 0.370 |
Why?
|
| Gingival Recession | 1 | 2010 | 1 | 0.370 |
Why?
|
| Furcation Defects | 1 | 2010 | 1 | 0.370 |
Why?
|
| Evidence-Based Dentistry | 1 | 2010 | 1 | 0.370 |
Why?
|
| Skilled Nursing Facilities | 4 | 2021 | 23 | 0.370 |
Why?
|
| Models, Economic | 1 | 2010 | 5 | 0.360 |
Why?
|
| Drug Resistance, Multiple | 5 | 2012 | 10 | 0.360 |
Why?
|
| Health Care Costs | 2 | 2010 | 75 | 0.360 |
Why?
|
| HIV Seropositivity | 2 | 2004 | 49 | 0.360 |
Why?
|
| Medical Records | 4 | 2005 | 31 | 0.350 |
Why?
|
| Multivariate Analysis | 11 | 2013 | 299 | 0.350 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 57 | 0.350 |
Why?
|
| Housekeeping, Hospital | 2 | 2008 | 5 | 0.340 |
Why?
|
| Child, Preschool | 8 | 2023 | 640 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2008 | 164 | 0.340 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2000 | 2 | 0.340 |
Why?
|
| Respiration, Artificial | 7 | 2015 | 101 | 0.330 |
Why?
|
| Hospitals, Urban | 8 | 2015 | 31 | 0.330 |
Why?
|
| Pharmacists | 2 | 2006 | 17 | 0.330 |
Why?
|
| Pseudomonas aeruginosa | 12 | 2017 | 53 | 0.330 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 8 | 0.320 |
Why?
|
| Soft Tissue Infections | 3 | 2011 | 22 | 0.320 |
Why?
|
| Infant | 8 | 2021 | 529 | 0.320 |
Why?
|
| Occupational Diseases | 1 | 2009 | 20 | 0.320 |
Why?
|
| Rectum | 7 | 2017 | 43 | 0.320 |
Why?
|
| Cohort Studies | 12 | 2024 | 1781 | 0.310 |
Why?
|
| Electronic Health Records | 2 | 2025 | 72 | 0.310 |
Why?
|
| Feces | 4 | 2017 | 103 | 0.300 |
Why?
|
| Acinetobacter | 1 | 2008 | 1 | 0.300 |
Why?
|
| Decontamination | 4 | 2008 | 10 | 0.300 |
Why?
|
| Disinfection | 3 | 2019 | 11 | 0.300 |
Why?
|
| DNA Fingerprinting | 2 | 2016 | 3 | 0.290 |
Why?
|
| Alcohols | 4 | 2007 | 6 | 0.290 |
Why?
|
| Drug Contamination | 3 | 2001 | 5 | 0.290 |
Why?
|
| Incidence | 11 | 2013 | 731 | 0.290 |
Why?
|
| Public Housing | 1 | 2007 | 4 | 0.290 |
Why?
|
| Cephalosporins | 7 | 2019 | 11 | 0.280 |
Why?
|
| Developing Countries | 2 | 2005 | 13 | 0.280 |
Why?
|
| Pneumonia | 5 | 1998 | 60 | 0.280 |
Why?
|
| Amikacin | 4 | 1998 | 5 | 0.280 |
Why?
|
| Serratia Infections | 2 | 2010 | 7 | 0.280 |
Why?
|
| Hospital Administration | 3 | 2021 | 21 | 0.280 |
Why?
|
| Education, Medical | 1 | 2007 | 39 | 0.280 |
Why?
|
| Dental Implantation, Endosseous | 2 | 2017 | 2 | 0.280 |
Why?
|
| Attitude of Health Personnel | 5 | 2021 | 146 | 0.280 |
Why?
|
| Phylogeny | 4 | 2023 | 42 | 0.270 |
Why?
|
| Hospital Units | 2 | 2004 | 8 | 0.270 |
Why?
|
| Drug Therapy, Combination | 5 | 2011 | 163 | 0.270 |
Why?
|
| Young Adult | 7 | 2022 | 1855 | 0.270 |
Why?
|
| Ceftazidime | 6 | 2001 | 8 | 0.270 |
Why?
|
| Bacteriological Techniques | 6 | 2017 | 17 | 0.270 |
Why?
|
| Ventilators, Mechanical | 3 | 2021 | 20 | 0.270 |
Why?
|
| Rifampin | 1 | 2006 | 2 | 0.260 |
Why?
|
| Minocycline | 1 | 2006 | 5 | 0.260 |
Why?
|
| Silver | 1 | 2006 | 4 | 0.260 |
Why?
|
| Problem-Based Learning | 1 | 2006 | 9 | 0.260 |
Why?
|
| Nose | 3 | 2013 | 27 | 0.260 |
Why?
|
| Treatment Outcome | 14 | 2018 | 3231 | 0.260 |
Why?
|
| Research | 1 | 2006 | 38 | 0.250 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2019 | 167 | 0.250 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 28 | 0.250 |
Why?
|
| Information Services | 1 | 2005 | 2 | 0.250 |
Why?
|
| Pneumonia, Bacterial | 3 | 2017 | 10 | 0.250 |
Why?
|
| Penicillins | 2 | 2002 | 8 | 0.250 |
Why?
|
| Dental Implants | 2 | 2017 | 9 | 0.250 |
Why?
|
| Patient Portals | 1 | 2025 | 5 | 0.250 |
Why?
|
| Nursing Records | 1 | 2005 | 7 | 0.250 |
Why?
|
| Culture Media | 5 | 2017 | 29 | 0.250 |
Why?
|
| Ciprofloxacin | 4 | 2003 | 10 | 0.250 |
Why?
|
| Infant, Newborn | 6 | 2021 | 588 | 0.240 |
Why?
|
| Gram-Negative Aerobic Bacteria | 3 | 2005 | 3 | 0.240 |
Why?
|
| Quality Indicators, Health Care | 1 | 2005 | 35 | 0.240 |
Why?
|
| Community Health Centers | 1 | 2005 | 13 | 0.240 |
Why?
|
| Subacute Care | 2 | 2021 | 4 | 0.240 |
Why?
|
| Streptococcus pneumoniae | 2 | 2002 | 5 | 0.240 |
Why?
|
| Dental Plaque | 1 | 2004 | 1 | 0.240 |
Why?
|
| Mouthwashes | 1 | 2004 | 6 | 0.240 |
Why?
|
| Binge Drinking | 1 | 2024 | 10 | 0.240 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 4459 | 0.230 |
Why?
|
| Health Behavior | 2 | 2021 | 136 | 0.230 |
Why?
|
| Masks | 2 | 2021 | 6 | 0.230 |
Why?
|
| Enterococcus faecium | 3 | 2001 | 11 | 0.230 |
Why?
|
| Dental Enamel Proteins | 1 | 2004 | 1 | 0.230 |
Why?
|
| Vaccination | 1 | 2004 | 31 | 0.220 |
Why?
|
| Hospitals, University | 3 | 2015 | 25 | 0.220 |
Why?
|
| Self Report | 1 | 2025 | 204 | 0.220 |
Why?
|
| Natural Language Processing | 1 | 2003 | 7 | 0.220 |
Why?
|
| Diarrhea | 2 | 2008 | 30 | 0.220 |
Why?
|
| Radiology | 1 | 2003 | 11 | 0.220 |
Why?
|
| Bioterrorism | 1 | 2003 | 4 | 0.220 |
Why?
|
| Coxiella burnetii | 1 | 2003 | 3 | 0.220 |
Why?
|
| Iodophors | 1 | 2023 | 2 | 0.220 |
Why?
|
| Radiography, Thoracic | 1 | 2003 | 25 | 0.220 |
Why?
|
| Unnecessary Procedures | 1 | 2004 | 24 | 0.220 |
Why?
|
| Colony Count, Microbial | 6 | 2015 | 13 | 0.220 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2020 | 5 | 0.220 |
Why?
|
| Hospital Information Systems | 1 | 2003 | 2 | 0.220 |
Why?
|
| Point-of-Care Systems | 1 | 2004 | 58 | 0.220 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2003 | 67 | 0.220 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 41 | 0.220 |
Why?
|
| Databases as Topic | 1 | 2003 | 14 | 0.220 |
Why?
|
| Technology | 1 | 2023 | 5 | 0.220 |
Why?
|
| Arizona | 1 | 2023 | 6 | 0.220 |
Why?
|
| Computers | 1 | 2003 | 18 | 0.210 |
Why?
|
| Digestive System Diseases | 1 | 2003 | 5 | 0.210 |
Why?
|
| Text Messaging | 1 | 2023 | 16 | 0.210 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2017 | 50 | 0.210 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2002 | 11 | 0.210 |
Why?
|
| Critical Illness | 4 | 2018 | 126 | 0.210 |
Why?
|
| Pandemics | 2 | 2023 | 227 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2010 | 130 | 0.210 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 49 | 0.210 |
Why?
|
| Gels | 1 | 2002 | 13 | 0.210 |
Why?
|
| Hospitals, County | 1 | 2002 | 3 | 0.210 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 13 | 0.210 |
Why?
|
| Hospitals, Private | 1 | 2002 | 3 | 0.210 |
Why?
|
| Water Supply | 1 | 2002 | 4 | 0.210 |
Why?
|
| Intestines | 3 | 2007 | 88 | 0.200 |
Why?
|
| Enterobacter | 7 | 2001 | 7 | 0.200 |
Why?
|
| Medication Systems | 1 | 2002 | 2 | 0.200 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 63 | 0.200 |
Why?
|
| Patient Transfer | 2 | 2012 | 22 | 0.200 |
Why?
|
| Penicillin Resistance | 1 | 2002 | 1 | 0.200 |
Why?
|
| Quinine | 1 | 2002 | 1 | 0.200 |
Why?
|
| Legislation, Hospital | 1 | 2001 | 1 | 0.190 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 74 | 0.190 |
Why?
|
| Gentamicins | 4 | 1995 | 13 | 0.190 |
Why?
|
| Skin Care | 3 | 2018 | 9 | 0.190 |
Why?
|
| Sucralfate | 2 | 1991 | 3 | 0.190 |
Why?
|
| Peer Review, Health Care | 1 | 2001 | 1 | 0.190 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 5 | 0.190 |
Why?
|
| Selection Bias | 1 | 2001 | 7 | 0.190 |
Why?
|
| Communicable Disease Control | 4 | 2023 | 10 | 0.180 |
Why?
|
| Spinal Puncture | 2 | 2000 | 25 | 0.180 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 4 | 0.180 |
Why?
|
| Homosexuality, Male | 2 | 2020 | 26 | 0.180 |
Why?
|
| Palliative Care | 1 | 2022 | 99 | 0.180 |
Why?
|
| Environmental Microbiology | 2 | 2017 | 5 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2021 | 53 | 0.180 |
Why?
|
| Meningitis, Bacterial | 1 | 2000 | 3 | 0.180 |
Why?
|
| Erythropoietin | 1 | 2001 | 45 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2000 | 26 | 0.180 |
Why?
|
| Neutropenia | 3 | 2008 | 14 | 0.180 |
Why?
|
| Costs and Cost Analysis | 3 | 2010 | 33 | 0.170 |
Why?
|
| Emergency Service, Hospital | 3 | 2012 | 245 | 0.170 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 847 | 0.170 |
Why?
|
| Fresh Water | 1 | 2020 | 5 | 0.170 |
Why?
|
| Digestive System | 3 | 2000 | 13 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2018 | 132 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2010 | 646 | 0.170 |
Why?
|
| Epidemiology | 2 | 1998 | 5 | 0.170 |
Why?
|
| Lung | 2 | 1998 | 159 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 2 | 1998 | 16 | 0.170 |
Why?
|
| Animals | 11 | 2017 | 3510 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 332 | 0.160 |
Why?
|
| Staphylococcus | 4 | 1993 | 9 | 0.160 |
Why?
|
| HIV-1 | 4 | 1995 | 221 | 0.160 |
Why?
|
| Medical Errors | 1 | 2019 | 25 | 0.160 |
Why?
|
| Tobramycin | 2 | 1998 | 7 | 0.160 |
Why?
|
| Drug Costs | 2 | 2010 | 13 | 0.160 |
Why?
|
| Species Specificity | 2 | 2016 | 37 | 0.160 |
Why?
|
| Risk | 7 | 2003 | 190 | 0.160 |
Why?
|
| Workload | 2 | 2012 | 31 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2013 | 107 | 0.160 |
Why?
|
| Genetic Variation | 3 | 2014 | 88 | 0.150 |
Why?
|
| Multilocus Sequence Typing | 4 | 2023 | 15 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 472 | 0.150 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 1300 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2015 | 618 | 0.150 |
Why?
|
| Specialties, Nursing | 1 | 1998 | 10 | 0.150 |
Why?
|
| Prognosis | 7 | 2022 | 739 | 0.150 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 1998 | 6 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 13 | 0.150 |
Why?
|
| Zidovudine | 3 | 1992 | 13 | 0.150 |
Why?
|
| Tuberculosis | 2 | 1997 | 18 | 0.150 |
Why?
|
| Hospital Bed Capacity, 500 and over | 2 | 2012 | 8 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 341 | 0.140 |
Why?
|
| American Hospital Association | 2 | 1994 | 2 | 0.140 |
Why?
|
| Fomites | 2 | 2008 | 3 | 0.140 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2017 | 4 | 0.140 |
Why?
|
| Bone-Implant Interface | 1 | 2017 | 6 | 0.140 |
Why?
|
| Regression Analysis | 6 | 2019 | 255 | 0.140 |
Why?
|
| Preservation, Biological | 1 | 1997 | 3 | 0.140 |
Why?
|
| Enterococcus faecalis | 1 | 1997 | 3 | 0.140 |
Why?
|
| Transfusion Reaction | 2 | 1995 | 6 | 0.140 |
Why?
|
| Environment, Controlled | 1 | 2017 | 1 | 0.140 |
Why?
|
| Greece | 1 | 2017 | 2 | 0.140 |
Why?
|
| Latin America | 1 | 2017 | 5 | 0.140 |
Why?
|
| Referral and Consultation | 3 | 2007 | 86 | 0.140 |
Why?
|
| Israel | 1 | 2017 | 16 | 0.140 |
Why?
|
| Feedback | 1 | 2017 | 33 | 0.140 |
Why?
|
| Bacterial Translocation | 4 | 2001 | 22 | 0.140 |
Why?
|
| Disinfectants | 2 | 2014 | 6 | 0.140 |
Why?
|
| Microbiology | 1 | 2016 | 2 | 0.140 |
Why?
|
| Endocarditis, Bacterial | 2 | 1996 | 10 | 0.140 |
Why?
|
| Osseointegration | 1 | 2017 | 67 | 0.140 |
Why?
|
| Escherichia coli Infections | 5 | 2014 | 23 | 0.140 |
Why?
|
| Substance Abuse, Intravenous | 2 | 1996 | 10 | 0.140 |
Why?
|
| Health Care Surveys | 6 | 2014 | 59 | 0.140 |
Why?
|
| Respiratory Tract Infections | 3 | 1996 | 23 | 0.140 |
Why?
|
| Gloves, Surgical | 1 | 1996 | 7 | 0.140 |
Why?
|
| Administration, Intranasal | 3 | 2023 | 27 | 0.130 |
Why?
|
| Professional Role | 1 | 2016 | 30 | 0.130 |
Why?
|
| Program Development | 1 | 2016 | 59 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2020 | 392 | 0.130 |
Why?
|
| Sinus Floor Augmentation | 1 | 2016 | 1 | 0.130 |
Why?
|
| Maxilla | 1 | 2016 | 2 | 0.130 |
Why?
|
| beta-Lactam Resistance | 3 | 2017 | 14 | 0.130 |
Why?
|
| Hydroxyapatites | 1 | 2016 | 9 | 0.130 |
Why?
|
| Bacterial Load | 2 | 2013 | 9 | 0.130 |
Why?
|
| Nontuberculous Mycobacteria | 2 | 2015 | 4 | 0.130 |
Why?
|
| Titanium | 1 | 2017 | 171 | 0.130 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2015 | 6 | 0.130 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 2 | 0.130 |
Why?
|
| Equipment and Supplies | 2 | 2010 | 10 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2016 | 26 | 0.130 |
Why?
|
| Data Collection | 3 | 2006 | 93 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2008 | 246 | 0.130 |
Why?
|
| Bone Matrix | 1 | 2016 | 29 | 0.130 |
Why?
|
| HIV Seronegativity | 1 | 1996 | 16 | 0.130 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1995 | 3 | 0.130 |
Why?
|
| Severity of Illness Index | 8 | 2008 | 913 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 1995 | 8 | 0.130 |
Why?
|
| Logistic Models | 6 | 2019 | 366 | 0.130 |
Why?
|
| Candidiasis | 1 | 2015 | 22 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 4 | 1988 | 37 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2015 | 21 | 0.130 |
Why?
|
| Interferon-alpha | 2 | 1992 | 30 | 0.130 |
Why?
|
| Insurance, Health | 3 | 2003 | 20 | 0.130 |
Why?
|
| Pregnancy | 1 | 2016 | 291 | 0.120 |
Why?
|
| Databases, Factual | 3 | 2019 | 329 | 0.120 |
Why?
|
| Nystatin | 1 | 1995 | 2 | 0.120 |
Why?
|
| Colistin | 1 | 1995 | 4 | 0.120 |
Why?
|
| Cluster Analysis | 5 | 2015 | 39 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 1689 | 0.120 |
Why?
|
| Bacteriuria | 2 | 2015 | 4 | 0.120 |
Why?
|
| Tuberculin Test | 2 | 2009 | 9 | 0.120 |
Why?
|
| Fluoroquinolones | 2 | 2023 | 10 | 0.120 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 34 | 0.120 |
Why?
|
| Cost Savings | 1 | 2014 | 36 | 0.120 |
Why?
|
| Dental Plaque Index | 2 | 2004 | 2 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2014 | 36 | 0.120 |
Why?
|
| Inpatients | 2 | 2009 | 132 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 51 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 4 | 2013 | 24 | 0.110 |
Why?
|
| Heart Failure | 1 | 2016 | 166 | 0.110 |
Why?
|
| Breast Diseases | 1 | 1993 | 5 | 0.110 |
Why?
|
| Blood | 2 | 2010 | 18 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2004 | 14 | 0.110 |
Why?
|
| Drug Prescriptions | 3 | 2003 | 21 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2021 | 244 | 0.110 |
Why?
|
| Algorithms | 3 | 2010 | 347 | 0.110 |
Why?
|
| Tooth Socket | 1 | 2013 | 1 | 0.110 |
Why?
|
| Abscess | 1 | 1993 | 28 | 0.110 |
Why?
|
| Drug Resistance | 2 | 2003 | 37 | 0.110 |
Why?
|
| Thailand | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hygiene | 3 | 2019 | 9 | 0.100 |
Why?
|
| APACHE | 2 | 2006 | 26 | 0.100 |
Why?
|
| Anti-HIV Agents | 2 | 2006 | 69 | 0.100 |
Why?
|
| Europe | 3 | 2014 | 64 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 3 | 2001 | 48 | 0.100 |
Why?
|
| Burnout, Professional | 1 | 2012 | 39 | 0.100 |
Why?
|
| Emotions | 1 | 2012 | 79 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 17 | 0.100 |
Why?
|
| Aspergillus niger | 1 | 1991 | 1 | 0.100 |
Why?
|
| Charcoal | 1 | 1991 | 1 | 0.100 |
Why?
|
| Penicillium | 1 | 1991 | 1 | 0.100 |
Why?
|
| Paecilomyces | 1 | 1991 | 2 | 0.100 |
Why?
|
| Models, Biological | 1 | 2014 | 311 | 0.100 |
Why?
|
| Pneumonia, Aspiration | 1 | 1991 | 6 | 0.100 |
Why?
|
| Lung Diseases, Fungal | 1 | 1991 | 10 | 0.100 |
Why?
|
| HIV | 1 | 2012 | 40 | 0.100 |
Why?
|
| Aspergillosis | 1 | 1991 | 12 | 0.100 |
Why?
|
| Brucella | 1 | 2011 | 3 | 0.100 |
Why?
|
| Brucellosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 33 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2012 | 116 | 0.100 |
Why?
|
| Comorbidity | 3 | 2019 | 457 | 0.090 |
Why?
|
| Plasmids | 5 | 2023 | 37 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 1991 | 30 | 0.090 |
Why?
|
| Serratia marcescens | 2 | 2010 | 7 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2012 | 98 | 0.090 |
Why?
|
| Thienamycins | 3 | 1998 | 5 | 0.090 |
Why?
|
| Imipenem | 3 | 1998 | 4 | 0.090 |
Why?
|
| Guided Tissue Regeneration, Periodontal | 1 | 2010 | 1 | 0.090 |
Why?
|
| Peritoneal Diseases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Medical Office Buildings | 1 | 2010 | 1 | 0.090 |
Why?
|
| Oropharynx | 1 | 1990 | 2 | 0.090 |
Why?
|
| Efficiency | 1 | 2010 | 20 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2010 | 36 | 0.090 |
Why?
|
| beta-Lactams | 3 | 2007 | 9 | 0.090 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2001 | 4 | 0.090 |
Why?
|
| Serratia | 3 | 2010 | 5 | 0.090 |
Why?
|
| Medicaid | 2 | 2003 | 29 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2008 | 152 | 0.090 |
Why?
|
| Knowledge Bases | 1 | 2010 | 2 | 0.090 |
Why?
|
| Azlocillin | 1 | 1989 | 1 | 0.090 |
Why?
|
| Linear Models | 1 | 2010 | 231 | 0.090 |
Why?
|
| Lice Infestations | 1 | 1989 | 1 | 0.080 |
Why?
|
| Urethral Diseases | 1 | 1989 | 3 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 2009 | 6 | 0.080 |
Why?
|
| Substance-Related Disorders | 4 | 2015 | 87 | 0.080 |
Why?
|
| Fever | 1 | 1989 | 30 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 443 | 0.080 |
Why?
|
| Models, Statistical | 3 | 2016 | 120 | 0.080 |
Why?
|
| Ventilators, Negative-Pressure | 1 | 2009 | 1 | 0.080 |
Why?
|
| Patient Admission | 2 | 2002 | 24 | 0.080 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 450 | 0.080 |
Why?
|
| Urinary Catheterization | 2 | 2008 | 7 | 0.080 |
Why?
|
| Acute Disease | 4 | 2023 | 187 | 0.080 |
Why?
|
| Surgical Flaps | 2 | 2013 | 44 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 74 | 0.080 |
Why?
|
| False Positive Reactions | 3 | 1998 | 26 | 0.080 |
Why?
|
| Sputum | 3 | 2015 | 20 | 0.080 |
Why?
|
| Pancreatitis | 2 | 2000 | 20 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 169 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2008 | 170 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 163 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 1077 | 0.080 |
Why?
|
| Foodborne Diseases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Lactams | 2 | 2005 | 4 | 0.080 |
Why?
|
| Los Angeles | 5 | 2000 | 10 | 0.070 |
Why?
|
| Bedding and Linens | 1 | 2007 | 6 | 0.070 |
Why?
|
| Folliculitis | 1 | 1987 | 1 | 0.070 |
Why?
|
| Porifera | 1 | 1987 | 1 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 119 | 0.070 |
Why?
|
| Renal Dialysis | 2 | 2015 | 115 | 0.070 |
Why?
|
| Random Allocation | 4 | 2000 | 116 | 0.070 |
Why?
|
| Aging | 1 | 1996 | 1429 | 0.070 |
Why?
|
| Health Facilities | 1 | 2007 | 22 | 0.070 |
Why?
|
| Software | 2 | 2006 | 63 | 0.070 |
Why?
|
| Cost Control | 1 | 2006 | 7 | 0.070 |
Why?
|
| Neoplasms | 1 | 1989 | 224 | 0.070 |
Why?
|
| Inservice Training | 1 | 2006 | 27 | 0.070 |
Why?
|
| Platinum | 1 | 2006 | 3 | 0.070 |
Why?
|
| Carbon | 1 | 2006 | 8 | 0.070 |
Why?
|
| Sex Factors | 3 | 2015 | 427 | 0.060 |
Why?
|
| Quality of Life | 1 | 2010 | 600 | 0.060 |
Why?
|
| Contact Tracing | 2 | 2011 | 5 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 3 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2006 | 32 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2006 | 138 | 0.060 |
Why?
|
| Survival Rate | 3 | 2003 | 308 | 0.060 |
Why?
|
| Bronchoscopy | 4 | 2003 | 24 | 0.060 |
Why?
|
| Cefotaxime | 1 | 1985 | 1 | 0.060 |
Why?
|
| AIDS Serodiagnosis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2004 | 5 | 0.060 |
Why?
|
| Tooth Discoloration | 1 | 2004 | 1 | 0.060 |
Why?
|
| Dental Implantation | 1 | 2004 | 2 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2001 | 201 | 0.060 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2005 | 16 | 0.060 |
Why?
|
| Aminoglycosides | 5 | 1987 | 9 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2017 | 256 | 0.060 |
Why?
|
| Patient Participation | 1 | 2005 | 42 | 0.060 |
Why?
|
| Research Design | 1 | 2006 | 188 | 0.060 |
Why?
|
| Sanitary Engineering | 1 | 1984 | 1 | 0.060 |
Why?
|
| Transducers | 3 | 1986 | 10 | 0.060 |
Why?
|
| Tooth Root | 1 | 2004 | 1 | 0.060 |
Why?
|
| Edetic Acid | 1 | 2004 | 3 | 0.060 |
Why?
|
| Periodontal Index | 1 | 2004 | 2 | 0.060 |
Why?
|
| Periodontal Pocket | 1 | 2004 | 2 | 0.060 |
Why?
|
| Periodontal Attachment Loss | 1 | 2004 | 3 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2004 | 13 | 0.060 |
Why?
|
| Radiology Information Systems | 1 | 2003 | 2 | 0.060 |
Why?
|
| Sentinel Surveillance | 1 | 2003 | 5 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2013 | 39 | 0.060 |
Why?
|
| Pancreatic Diseases | 1 | 1983 | 2 | 0.060 |
Why?
|
| Monitoring, Physiologic | 3 | 1986 | 69 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 3 | 0.060 |
Why?
|
| Soaps | 3 | 2010 | 7 | 0.060 |
Why?
|
| Quarantine | 1 | 2023 | 2 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 70 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2003 | 1 | 0.050 |
Why?
|
| Blood-Borne Pathogens | 1 | 2003 | 3 | 0.050 |
Why?
|
| Computer Communication Networks | 1 | 2003 | 3 | 0.050 |
Why?
|
| Computer Systems | 1 | 2003 | 7 | 0.050 |
Why?
|
| Sarcoidosis | 1 | 1983 | 14 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2021 | 76 | 0.050 |
Why?
|
| Facility Design and Construction | 1 | 2003 | 2 | 0.050 |
Why?
|
| Bone Regeneration | 1 | 2004 | 76 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2003 | 12 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 21 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 26 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 55 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 148 | 0.050 |
Why?
|
| Hospitals, Municipal | 1 | 2002 | 1 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2002 | 7 | 0.050 |
Why?
|
| New York City | 2 | 2000 | 15 | 0.050 |
Why?
|
| Hospital Departments | 1 | 2002 | 4 | 0.050 |
Why?
|
| Blood Pressure Determination | 2 | 1986 | 12 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2002 | 2 | 0.050 |
Why?
|
| Medication Errors | 1 | 2002 | 14 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 2001 | 178 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2022 | 5 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2002 | 37 | 0.050 |
Why?
|
| Base Sequence | 1 | 2002 | 90 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 111 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 574 | 0.050 |
Why?
|
| Cephalosporin Resistance | 1 | 2001 | 1 | 0.050 |
Why?
|
| Animal Husbandry | 1 | 2001 | 7 | 0.050 |
Why?
|
| North America | 1 | 2001 | 42 | 0.050 |
Why?
|
| Gift Giving | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hand Sanitizers | 1 | 2021 | 3 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2002 | 88 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 27 | 0.050 |
Why?
|
| Methicillin | 1 | 2021 | 7 | 0.050 |
Why?
|
| Glucagon | 1 | 2001 | 7 | 0.050 |
Why?
|
| Epoetin Alfa | 1 | 2001 | 20 | 0.050 |
Why?
|
| Confidentiality | 1 | 2001 | 5 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 38 | 0.050 |
Why?
|
| Health Surveys | 1 | 2021 | 85 | 0.050 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2001 | 4 | 0.050 |
Why?
|
| Lung Diseases | 2 | 1998 | 42 | 0.050 |
Why?
|
| Meningitis | 2 | 1984 | 7 | 0.050 |
Why?
|
| Health Education | 1 | 2001 | 48 | 0.050 |
Why?
|
| Geography | 2 | 2011 | 12 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2001 | 151 | 0.040 |
Why?
|
| Peptides | 1 | 2001 | 104 | 0.040 |
Why?
|
| Waste Disposal, Fluid | 1 | 2020 | 4 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2020 | 11 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 664 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 74 | 0.040 |
Why?
|
| Ecosystem | 1 | 2020 | 16 | 0.040 |
Why?
|
| California | 1 | 2019 | 30 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2000 | 44 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 183 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 199 | 0.040 |
Why?
|
| Leucine | 1 | 1999 | 10 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1999 | 6 | 0.040 |
Why?
|
| Enteral Nutrition | 2 | 1998 | 58 | 0.040 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 119 | 0.040 |
Why?
|
| Bias | 1 | 1999 | 37 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 1999 | 1 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1998 | 4 | 0.040 |
Why?
|
| Ear, Middle | 1 | 1999 | 8 | 0.040 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1978 | 1 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 129 | 0.040 |
Why?
|
| Imidazoles | 1 | 1999 | 53 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 1998 | 110 | 0.040 |
Why?
|
| Homosexuality | 2 | 1995 | 6 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 1998 | 9 | 0.040 |
Why?
|
| Patient Care Management | 1 | 1998 | 16 | 0.040 |
Why?
|
| Hemodynamics | 1 | 1998 | 57 | 0.040 |
Why?
|
| Gram-Positive Cocci | 2 | 2008 | 4 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1998 | 19 | 0.040 |
Why?
|
| Hepatitis B | 2 | 1981 | 12 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 140 | 0.040 |
Why?
|
| Dental Prosthesis Design | 1 | 2017 | 1 | 0.040 |
Why?
|
| Acid Etching, Dental | 1 | 2017 | 2 | 0.040 |
Why?
|
| Dental Alloys | 1 | 2017 | 4 | 0.040 |
Why?
|
| Virus Diseases | 1 | 1997 | 9 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 71 | 0.040 |
Why?
|
| Freezing | 1 | 1997 | 11 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 2 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 76 | 0.040 |
Why?
|
| Mycoses | 1 | 1997 | 21 | 0.040 |
Why?
|
| Swine | 1 | 2017 | 71 | 0.040 |
Why?
|
| Agranulocytosis | 2 | 1989 | 3 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 61 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1997 | 27 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 110 | 0.030 |
Why?
|
| Research Personnel | 1 | 2017 | 18 | 0.030 |
Why?
|
| Implants, Experimental | 1 | 2017 | 32 | 0.030 |
Why?
|
| Surface Properties | 1 | 2017 | 134 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2012 | 85 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 1996 | 6 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 1996 | 9 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2016 | 4 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 49 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 1996 | 3 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 1996 | 6 | 0.030 |
Why?
|
| Materials Testing | 1 | 2017 | 130 | 0.030 |
Why?
|
| Age Distribution | 1 | 1996 | 84 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1996 | 75 | 0.030 |
Why?
|
| Cytokines | 1 | 1998 | 212 | 0.030 |
Why?
|
| Ceramics | 1 | 2016 | 20 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 1996 | 4 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1996 | 43 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 118 | 0.030 |
Why?
|
| Bone Substitutes | 1 | 2016 | 26 | 0.030 |
Why?
|
| Leadership | 1 | 2017 | 97 | 0.030 |
Why?
|
| Histoplasma | 1 | 1995 | 4 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1996 | 27 | 0.030 |
Why?
|
| Insurance, Hospitalization | 1 | 1995 | 2 | 0.030 |
Why?
|
| Candida | 1 | 2015 | 10 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 50 | 0.030 |
Why?
|
| Gram-Positive Bacteria | 2 | 2009 | 9 | 0.030 |
Why?
|
| Guatemala | 1 | 1995 | 1 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 7 | 0.030 |
Why?
|
| Diffusion | 2 | 2014 | 24 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 88 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 1975 | 9 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1975 | 16 | 0.030 |
Why?
|
| Bisexuality | 1 | 1995 | 7 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 12 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 29 | 0.030 |
Why?
|
| Florida | 4 | 1995 | 20 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2016 | 106 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 52 | 0.030 |
Why?
|
| Gastric Juice | 1 | 2015 | 2 | 0.030 |
Why?
|
| Drinking Water | 1 | 2015 | 2 | 0.030 |
Why?
|
| Pulmonary Atelectasis | 1 | 2015 | 4 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1995 | 45 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tibia | 1 | 2017 | 230 | 0.030 |
Why?
|
| Pentazocine | 2 | 1985 | 2 | 0.030 |
Why?
|
| Tripelennamine | 2 | 1985 | 2 | 0.030 |
Why?
|
| Delirium | 1 | 2015 | 13 | 0.030 |
Why?
|
| Forecasting | 1 | 1995 | 92 | 0.030 |
Why?
|
| Syria | 1 | 2014 | 1 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2015 | 17 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1995 | 98 | 0.030 |
Why?
|
| Minority Groups | 1 | 1995 | 82 | 0.030 |
Why?
|
| Hand Hygiene | 1 | 2014 | 2 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 23 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2001 | 322 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 18 | 0.030 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 1994 | 1 | 0.030 |
Why?
|
| Planning Techniques | 1 | 1994 | 10 | 0.030 |
Why?
|
| Campylobacter Infections | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chickens | 1 | 2014 | 29 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1995 | 396 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 80 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 27 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 18 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2013 | 15 | 0.030 |
Why?
|
| Clindamycin | 1 | 1993 | 1 | 0.030 |
Why?
|
| Coagulase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Nafcillin | 1 | 1993 | 1 | 0.030 |
Why?
|
| Publishing | 1 | 1994 | 38 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 116 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 6 | 0.030 |
Why?
|
| Rats | 3 | 2001 | 649 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 187 | 0.030 |
Why?
|
| Drainage | 1 | 1993 | 43 | 0.030 |
Why?
|
| Alveolar Process | 1 | 2013 | 1 | 0.030 |
Why?
|
| Alveolar Ridge Augmentation | 1 | 2013 | 1 | 0.030 |
Why?
|
| Periodontium | 1 | 2013 | 1 | 0.030 |
Why?
|
| Esthetics, Dental | 1 | 2013 | 2 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1993 | 96 | 0.030 |
Why?
|
| Indiana | 2 | 2011 | 14 | 0.030 |
Why?
|
| Propensity Score | 1 | 2012 | 32 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 157 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 53 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 554 | 0.030 |
Why?
|
| HIV Core Protein p24 | 1 | 1992 | 7 | 0.030 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1991 | 6 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2011 | 6 | 0.020 |
Why?
|
| Virulence | 1 | 2011 | 8 | 0.020 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gastric Acidity Determination | 1 | 1991 | 2 | 0.020 |
Why?
|
| Mexico | 1 | 2011 | 18 | 0.020 |
Why?
|
| Milk | 1 | 2011 | 14 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2011 | 7 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1991 | 39 | 0.020 |
Why?
|
| Travel | 1 | 2011 | 12 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1991 | 15 | 0.020 |
Why?
|
| Prednisone | 1 | 1991 | 58 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 2 | 0.020 |
Why?
|
| Clone Cells | 1 | 2011 | 9 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1993 | 177 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 54 | 0.020 |
Why?
|
| Bone Transplantation | 1 | 2013 | 184 | 0.020 |
Why?
|
| Syringes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2010 | 28 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 55 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 275 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 132 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 104 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 111 | 0.020 |
Why?
|
| Age Factors | 2 | 2004 | 716 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1991 | 209 | 0.020 |
Why?
|
| Antisepsis | 2 | 2003 | 2 | 0.020 |
Why?
|
| Automation | 1 | 2010 | 8 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2010 | 9 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 1989 | 2 | 0.020 |
Why?
|
| Ileum | 2 | 2001 | 17 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 183 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1989 | 12 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 102 | 0.020 |
Why?
|
| Escherichia coli O157 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Salmonella | 1 | 2008 | 4 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 1999 | 66 | 0.020 |
Why?
|
| Citrobacter | 1 | 1987 | 1 | 0.020 |
Why?
|
| Oxacillin | 1 | 1987 | 2 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 8 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2006 | 11 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1991 | 509 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 46 | 0.020 |
Why?
|
| Transducers, Pressure | 1 | 1986 | 4 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2006 | 12 | 0.020 |
Why?
|
| Diphtheria | 1 | 1985 | 1 | 0.020 |
Why?
|
| Nurses | 1 | 2006 | 50 | 0.020 |
Why?
|
| Patients | 1 | 2006 | 32 | 0.020 |
Why?
|
| Penicillanic Acid | 1 | 2005 | 2 | 0.020 |
Why?
|
| Piperacillin | 1 | 2005 | 2 | 0.020 |
Why?
|
| Metronidazole | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2005 | 5 | 0.020 |
Why?
|
| Deltaretrovirus | 1 | 1985 | 1 | 0.020 |
Why?
|
| Blood Donors | 1 | 1985 | 4 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 22 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1986 | 190 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 5 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1983 | 1 | 0.010 |
Why?
|
| Moxalactam | 1 | 1983 | 1 | 0.010 |
Why?
|
| Ibuprofen | 1 | 1984 | 12 | 0.010 |
Why?
|
| Milk, Human | 1 | 1986 | 176 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1984 | 35 | 0.010 |
Why?
|
| Echinococcosis, Hepatic | 1 | 1983 | 1 | 0.010 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 1983 | 1 | 0.010 |
Why?
|
| Mebendazole | 1 | 1983 | 1 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 1983 | 8 | 0.010 |
Why?
|
| Resource Allocation | 1 | 2003 | 4 | 0.010 |
Why?
|
| Blood Pressure Monitors | 1 | 2002 | 1 | 0.010 |
Why?
|
| Umbilical Arteries | 1 | 2002 | 3 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 170 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 2002 | 6 | 0.010 |
Why?
|
| Plasmodium falciparum | 1 | 1981 | 2 | 0.010 |
Why?
|
| Malaria | 1 | 1981 | 3 | 0.010 |
Why?
|
| Glucagon-Like Peptides | 1 | 2001 | 2 | 0.010 |
Why?
|
| Glucagon-Like Peptide 2 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Jejunum | 1 | 2001 | 10 | 0.010 |
Why?
|
| Serotyping | 3 | 1987 | 6 | 0.010 |
Why?
|
| Permeability | 1 | 2001 | 111 | 0.010 |
Why?
|
| Conjugation, Genetic | 2 | 1996 | 4 | 0.010 |
Why?
|
| Weight Loss | 1 | 2001 | 105 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2000 | 12 | 0.010 |
Why?
|
| Klebsiella | 1 | 1980 | 1 | 0.010 |
Why?
|
| Netilmicin | 1 | 1980 | 1 | 0.010 |
Why?
|
| Pseudomonadaceae | 1 | 1980 | 1 | 0.010 |
Why?
|
| Cecum | 1 | 2000 | 13 | 0.010 |
Why?
|
| Urine | 1 | 1980 | 9 | 0.010 |
Why?
|
| Pancreas | 1 | 2000 | 29 | 0.010 |
Why?
|
| Dogs | 1 | 2000 | 176 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2000 | 105 | 0.010 |
Why?
|
| Amylases | 1 | 1999 | 5 | 0.010 |
Why?
|
| Rheumatic Fever | 1 | 1979 | 3 | 0.010 |
Why?
|
| Gonorrhea | 1 | 1979 | 7 | 0.010 |
Why?
|
| Haemophilus Infections | 1 | 1999 | 1 | 0.010 |
Why?
|
| Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1985 | 827 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 182 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1978 | 1 | 0.010 |
Why?
|
| Cefazolin | 2 | 1988 | 3 | 0.010 |
Why?
|
| Hepatitis | 1 | 1977 | 5 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 1977 | 4 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1977 | 6 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1977 | 29 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1997 | 4 | 0.010 |
Why?
|
| Mesentery | 1 | 1997 | 5 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 19 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 52 | 0.010 |
Why?
|
| Sterilization | 1 | 1976 | 8 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1996 | 47 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1975 | 12 | 0.010 |
Why?
|
| North Carolina | 1 | 1995 | 11 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1975 | 17 | 0.010 |
Why?
|
| Georgia | 1 | 1975 | 9 | 0.010 |
Why?
|
| Laboratories | 1 | 1975 | 8 | 0.010 |
Why?
|
| Leukocytes | 1 | 1975 | 35 | 0.010 |
Why?
|
| Liver | 1 | 1975 | 144 | 0.010 |
Why?
|
| Veterans | 1 | 1995 | 75 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1993 | 2 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 24 | 0.010 |
Why?
|
| Kinetics | 1 | 1993 | 179 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1992 | 2 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1992 | 24 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 62 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1992 | 37 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1992 | 69 | 0.010 |
Why?
|
| Mutation | 2 | 1983 | 325 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1992 | 100 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1989 | 19 | 0.010 |
Why?
|
| Peritoneum | 1 | 1986 | 16 | 0.000 |
Why?
|
| Disposable Equipment | 1 | 1986 | 1 | 0.000 |
Why?
|
| Diphtheria Toxoid | 1 | 1985 | 1 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1985 | 4 | 0.000 |
Why?
|
| Immunization | 1 | 1985 | 15 | 0.000 |
Why?
|
| Seasons | 1 | 1985 | 23 | 0.000 |
Why?
|
| Cardiac Catheterization | 1 | 1986 | 61 | 0.000 |
Why?
|
| Viremia | 1 | 1985 | 9 | 0.000 |
Why?
|
| HIV Antibodies | 1 | 1985 | 15 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1985 | 36 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1985 | 49 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1984 | 26 | 0.000 |
Why?
|
| Cefamandole | 1 | 1983 | 1 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1983 | 7 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1983 | 79 | 0.000 |
Why?
|
| Africa, Eastern | 1 | 1981 | 1 | 0.000 |
Why?
|
| Proteus Infections | 1 | 1976 | 1 | 0.000 |
Why?
|